Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Irinotecan in Relapsed or Refractory SCLC
NCT04173325Phase 1Terminated
- Sponsor
- Augusta University
- Start
- Jan 2020
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab in small cell lung cancer (SCLC), sponsored by Augusta University. Primary endpoint: Adverse Events at 1 year. Started Jan 2020; status: terminated.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04173325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04173325.